Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NGX0XFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17CUWlEPTB;MD6wNFY3QSEQvF2= NWLXNZJPW0GQR1XS
MV-4-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEG1PFYh|ryP M3:yXHNCVkeHUh?=
NKM-1 M4nBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7wfnZKSzVyPUCuNFE3QTlizszN M3fVU3NCVkeHUh?=
ML-2 M2rQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX5TWM2OD1yLkCxPVg{KM7:TR?= M1[xVHNCVkeHUh?=
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;JTWM2OD1yLkCyN|E1KM7:TR?= M3q0c3NCVkeHUh?=
RS4-11 NXrLNIt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LyUmlEPTB;MD6wNlU5PyEQvF2= NYnKVJNtW0GQR1XS
HL-60 NIfKdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjSb2FKSzVyPUCuNFI6ODhizszN M4j3b3NCVkeHUh?=
KY821 NGDvSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G4PGlEPTB;MD6wNlk4PSEQvF2= M2HSbXNCVkeHUh?=
ECC10 NUDae3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PGV2lEPTB;MD6wN|c6OiEQvF2= MVLTRW5ITVJ?
NCI-H720 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnSPFNIUUN3ME2wMlA1ODFzIN88US=> MWfTRW5ITVJ?
QIMR-WIL NYXjUnR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMESyPFch|ryP M1fXUXNCVkeHUh?=
KG-1 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37VUmlEPTB;MD6wOFQ5PiEQvF2= M{jqV3NCVkeHUh?=
TGW M2HFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMES2N|Mh|ryP M{foPXNCVkeHUh?=
ATN-1 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[xUGlEPTB;MD6wOFc{OyEQvF2= M1L6WHNCVkeHUh?=
RH-18 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwME[wOFgh|ryP NHTrdlhUSU6JRWK=
EW-18 M2PhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTaTWM2OD1yLkC2PFQyKM7:TR?= Ml\ZV2FPT0WU
NB17 NEOzb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfyVnJMUUN3ME2wMlA4OTJ2IN88US=> NEXyPI5USU6JRWK=
SK-NEP-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjpVIhKSzVyPUCuNFczOTNizszN Ml:5V2FPT0WU
P12-ICHIKAWA NXzzeFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTaTWM2OD1yLkC3O|c5KM7:TR?= NXPiOXA4W0GQR1XS
KARPAS-45 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEe4NVUh|ryP NYj2V2FWW0GQR1XS
EW-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHNU2pKSzVyPUCuNFgxPTNizszN MVnTRW5ITVJ?
NB13 NWLQbXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fKVmlEPTB;MD6wPFIxOyEQvF2= MXTTRW5ITVJ?
NCI-H209 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsTWM2OD1yLkC4O|A1KM7:TR?= NUCxW5pWW0GQR1XS
NCI-H1092 NV\SVFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\odVJKSzVyPUCuNVAzPzVizszN NXH2T25TW0GQR1XS
NH-12 NFHYUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTDfXN6UUN3ME2wMlExPzR2IN88US=> MYrTRW5ITVJ?
697 NUH3UGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[4dZNwUUN3ME2wMlExQDN7IN88US=> MXLTRW5ITVJ?
KE-37 NXfwZVNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjlUG5KSzVyPUCuNVE{PyEQvF2= NFP2e|NUSU6JRWK=
MOLT-4 M2rRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\WcZJJUUN3ME2wMlE2OTZ7IN88US=> NYHpXotRW0GQR1XS
CHP-134 NIHzSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnScIF1UUN3ME2wMlE3OzB4IN88US=> NWnvSm0yW0GQR1XS
D-283MED MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTseVRKSzVyPUCuNVc3QDZizszN MUPTRW5ITVJ?
LU-135 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUi1OVIh|ryP MVTTRW5ITVJ?
LU-134-A M4LOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTWU4VKSzVyPUCuNVg3PzFizszN NEPtd5RUSU6JRWK=
EM-2 M{ixUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjLdGRKSzVyPUCuNVk6OThizszN MnHYV2FPT0WU
LU-139 NXTFWWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMkC0PVgh|ryP MXHTRW5ITVJ?
ALL-PO MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzScpJKSzVyPUCuNlE6QDhizszN NHzBSIVUSU6JRWK=
NB12 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMkOxNVUh|ryP NInBZoZUSU6JRWK=
KP-N-YN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3NmlEPTB;MD6yN|U4OyEQvF2= M1K4XHNCVkeHUh?=
BEN NGXsV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml75TWM2OD1yLkKzPVY5KM7:TR?= MlKzV2FPT0WU
HCC1569 NEnNcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLoem13UUN3ME2wMlI2OTB4IN88US=> MXTTRW5ITVJ?
HuO9 M1PQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HoOWlEPTB;MD6yOlcyPSEQvF2= NF3LdJZUSU6JRWK=
WM-115 NVO0dJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLBWZlKSzVyPUCuNlc4OzhizszN M3\WUnNCVkeHUh?=
CCRF-CEM M1rMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjubos3UUN3ME2wMlM{PTJ7IN88US=> MYfTRW5ITVJ?
IST-SL1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwM{WzOFMh|ryP NUTjXJhkW0GQR1XS
BE-13 NIXFUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6TmlEPTB;MD6zOlQ2QSEQvF2= NUGydIt[W0GQR1XS
COR-L88 NEDxXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwM{[1OEDPxE1? M{f0b3NCVkeHUh?=
DOHH-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\nTWM2OD1yLkSxNFI{KM7:TR?= NITtXGJUSU6JRWK=
A704 M4Pyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS5NpNKSzVyPUCuOFI3PyEQvF2= NVe3d2pXW0GQR1XS
KNS-81-FD NFW2XVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7zTWM2OD1yLkS0NFE4KM7:TR?= MmHYV2FPT0WU
RPMI-8226 NVL6WGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XqdmlEPTB;MD60OVY2OiEQvF2= MVrTRW5ITVJ?
TGBC24TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3vTWM2OD1yLkS1O|c5KM7:TR?= NHvhdHlUSU6JRWK=
NCI-H1304 NF3NTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmyTWM2OD1yLkS2NVU4KM7:TR?= MkTXV2FPT0WU
MOLT-13 NH\lcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7BTWM2OD1yLkS2OlE{KM7:TR?= NWPEOJh2W0GQR1XS
EW-22 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNE[2O|Eh|ryP M2DCSHNCVkeHUh?=
MS-1 M1\Zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DncWlEPTB;MD60Olk{OyEQvF2= M3\IZ3NCVkeHUh?=
RMG-I MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD1yLkS5OFY1KM7:TR?= M4LhenNCVkeHUh?=
NTERA-S-cl-D1 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnM[XFKSzVyPUCuOVAxOTlizszN MnzzV2FPT0WU
NCI-H1048 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPTOGpZUUN3ME2wMlUxQTV|IN88US=> NYjjW3RMW0GQR1XS
SW1417 NInSN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CydGlEPTB;MD61OVQ{QCEQvF2= M1LjVXNCVkeHUh?=
DB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXiO4dGUUN3ME2wMlU4ODhizszN Ml;1V2FPT0WU
MEG-01 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlUJFMUUN3ME2wMlU5OzJizszN NVTGcYdlW0GQR1XS
EW-13 M1nhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPWXIJKSzVyPUCuOVg{PDFizszN NVKy[HZUW0GQR1XS
LAMA-84 NFnwVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r5c2lEPTB;MD61PVIxPyEQvF2= MYLTRW5ITVJ?
J-RT3-T3-5 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwNkC4NFgh|ryP NYjEZ2RGW0GQR1XS
MOLT-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rZfGlEPTB;MD62OVI3PCEQvF2= M1PEUnNCVkeHUh?=
DU-4475 NFXEblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn1SWpKSzVyPUCuOlU1OjdizszN Mn;ZV2FPT0WU
HAL-01 M1jHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrkfGlkUUN3ME2wMlczPTR7IN88US=> NEHk[HNUSU6JRWK=
RD M{X5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL0b3pKSzVyPUCuO|U5QTlizszN MVXTRW5ITVJ?
OAW-28 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF22eYFKSzVyPUCuO|g{PyEQvF2= M3[yVXNCVkeHUh?=
HCC38 NIq3UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M161[2lEPTB;MD64NFE6KM7:TR?= NVv3dWtUW0GQR1XS
NMC-G1 NX;tSZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwOEGxNlEh|ryP MYPTRW5ITVJ?
EW-16 M33INGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XzWGlEPTB;MD64NVMzQCEQvF2= NEmzNm1USU6JRWK=
DU-145 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm1[GlKSzVyPUCuPFk6OjNizszN Mn\QV2FPT0WU
HPAF-II NFHOVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7KboNKSzVyPUCuPVI3OjhizszN NFKzeoZUSU6JRWK=
A427 MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLSbZZmUUN3ME2wMlk{ODJ{IN88US=> M135U3NCVkeHUh?=
PA-1 M3:4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TPOGlEPTB;MD65OVY1OiEQvF2= MXzTRW5ITVJ?
OAW-42 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwOU[xOFYh|ryP MVHTRW5ITVJ?
L-428 NV3MbXZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2cGJKSzVyPUGuNFEzPSEQvF2= MWHTRW5ITVJ?
COLO-824 NWj1N2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMEG3NFgh|ryP MWrTRW5ITVJ?
P30-OHK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkOIVKSzVyPUGuNFQ3QDhizszN MVHTRW5ITVJ?
NCI-H2170 M{DFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwME[yN{DPxE1? MYPTRW5ITVJ?
HCC2998 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwMEexN|Uh|ryP NV21S|dsW0GQR1XS
NB14 M2jwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnF[49mUUN3ME2xMlE{PzR6IN88US=> MlP6V2FPT0WU
TGBC1TKB MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHOV|BKSzVyPUGuNVQyPTJizszN MnG4V2FPT0WU
KP-N-YS NFP1b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnZTWM2OD1zLkG2NlM3KM7:TR?= NHzvOpFUSU6JRWK=
CAL-120 NGXt[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwMU[0Nlkh|ryP MmL1V2FPT0WU
SBC-1 NIP6XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvlT3BrUUN3ME2xMlE6ODV|IN88US=> NGnp[JJUSU6JRWK=
C32 NVXjWWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fxTWlEPTB;MT6xPVA5QCEQvF2= MXfTRW5ITVJ?
HCC2157 NFy1S5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPTeHk1UUN3ME2xMlE6PDl2IN88US=> Mkn4V2FPT0WU
COLO-792 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwMkCwO|Eh|ryP NGPSZlZUSU6JRWK=
ES7 NHfEXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0SIpKSzVyPUGuNlc6PTFizszN NYfvXJJYW0GQR1XS
HEL NFOzfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:5TWM2OD1zLkOxNFI6KM7:TR?= MV;TRW5ITVJ?
ES4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS4TWM2OD1zLkO0PVk5KM7:TR?= NIqxUY9USU6JRWK=
NCI-SNU-1 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD1zLkO2OVU2KM7:TR?= M{fzUnNCVkeHUh?=
MDA-MB-415 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwM{i4OUDPxE1? NFLodG1USU6JRWK=
NCI-H2342 NHnOTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i3bWlEPTB;MT60NFI3QSEQvF2= NH;6OFdUSU6JRWK=
NB69 NHLFfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzJOo9LUUN3ME2xMlQ3OjdzIN88US=> M1fjbXNCVkeHUh?=
D-247MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXwSpVGUUN3ME2xMlUyOTJ{IN88US=> NYnlZ4tyW0GQR1XS
SCC-4 NEnJ[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDy[XJYUUN3ME2xMlU6QDh5IN88US=> NVzPUZFFW0GQR1XS
HuH-7 M175PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwNkeyPVMh|ryP NGTKNHVUSU6JRWK=
A388 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rUT2lEPTB;MT62PFczPCEQvF2= MX3TRW5ITVJ?
Calu-3 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnUc3lKSzVyPUGuO|A3QTdizszN MXfTRW5ITVJ?
NCI-H1648 Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwN{G0NVgh|ryP MYjTRW5ITVJ?
NCI-H2052 NHT0fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwN{KyNFEh|ryP MUPTRW5ITVJ?
Ramos-2G6-4C10 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33MfmlEPTB;MT63N|Y2PiEQvF2= NWjBOHNxW0GQR1XS
DEL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe5fohKSzVyPUGuO|Q3QTJizszN M3jwUnNCVkeHUh?=
SNU-423 NWr5ZYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTITWM2OD1zLke4NVU4KM7:TR?= MWXTRW5ITVJ?
COR-L23 M3SxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwN{m4O|Qh|ryP MXHTRW5ITVJ?
OMC-1 M3;2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELKSFlKSzVyPUGuPFYxOTZizszN M3fZe3NCVkeHUh?=
EW-11 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnuR|BFUUN3ME2xMlk2PjV5IN88US=> Ml[5V2FPT0WU
HSC-3 M{fqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvBTWM2OD1zLkm2N|Y2KM7:TR?= NUL0[IdyW0GQR1XS
MLMA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwOU[2O|ch|ryP M3vUdnNCVkeHUh?=
RCM-1 NHLCbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwMECzPVkh|ryP MVvTRW5ITVJ?
MFE-280 NY\FRnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrsbZlmUUN3ME2yMlAzQDR6IN88US=> NWDjTmxuW0GQR1XS
ES8 NHX0RllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fVbWlEPTB;Mj6yOVQ4OSEQvF2= NUfRephFW0GQR1XS
TE-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Phb2lEPTB;Mj6yPVQ4OyEQvF2= MWPTRW5ITVJ?
HuO-3N1 NFPsV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfpXmNKSzVyPUKuOFg4QCEQvF2= NV7pcGVxW0GQR1XS
MHH-NB-11 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4fmZKSzVyPUKuOVEyPThizszN NVXYbo46W0GQR1XS
TGBC11TKB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfJTWM2OD1{LkW3OlgyKM7:TR?= MnzoV2FPT0WU
HOP-92 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rVRmlEPTB;Mj61PFc1OyEQvF2= NFXLe5pUSU6JRWK=
IGR-1 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3WFlKSzVyPUKuOlIxOzVizszN NH7SeppUSU6JRWK=
GOTO M1zzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojZTWM2OD1{Lk[1N|c4KM7:TR?= Moj2V2FPT0WU
NCI-H1650 NXW5dYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnPcYgxUUN3ME2yMlczOjF3IN88US=> MkHSV2FPT0WU
NCI-H1581 M{Premdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzGTWM2OD1{Lke5OlgyKM7:TR?= NWLLdW9FW0GQR1XS
NCI-H2405 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHzTWM2OD1{LkiyO|gzKM7:TR?= MWnTRW5ITVJ?
U-118-MG M2roR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLUVWtKSzVyPUKuPVY1QTFizszN NYXOcXVnW0GQR1XS
DoTc2-4510 M{jXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr2TW5KSzVyPUOuNFE1OTdizszN NGD4R4JUSU6JRWK=
NCI-H596 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DkfmlEPTB;Mz6wOFk6PyEQvF2= NHe4dJVUSU6JRWK=
MPP-89 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwMEW2OlYh|ryP MVjTRW5ITVJ?
GCIY M2nsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;RVGlEPTB;Mz6yNFQ6OSEQvF2= MV\TRW5ITVJ?
SW626 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXiTWM2OD1|LkK0OVQ{KM7:TR?= MkXaV2FPT0WU
OCI-AML2 NH3CZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjNO3NKSzVyPUOuN|EzPzJizszN NFLzcZlUSU6JRWK=
NBsusSR M{P5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v0[mlEPTB;Mz6zOFk{QCEQvF2= NFOxd|ZUSU6JRWK=
AN3-CA M3fXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ldmxKSzVyPUOuOFQzOzhizszN NFX0WFZUSU6JRWK=
EFM-19 NVXDUZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNwNEizN|kh|ryP MUHTRW5ITVJ?
RVH-421 NV\NeoY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILMeIpKSzVyPUOuOVY5PzdizszN NILQOoVUSU6JRWK=
5637 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES5bINKSzVyPUOuOlEyODNizszN MUPTRW5ITVJ?
PANC-08-13 NELuNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHVS|hPUUN3ME2zMlY{PDd{IN88US=> NWewU4JXW0GQR1XS
H9 NGXLOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnyTWM2OD1|Lk[3NVQ1KM7:TR?= NWDIUnUyW0GQR1XS
KARPAS-299 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nFOWlEPTB;Mz62O|M3OSEQvF2= NWrZWnJiW0GQR1XS
TE-5 NFr2O|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXK[VdQUUN3ME2zMlcxPzB7IN88US=> M4rlNHNCVkeHUh?=
NOS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rXZ2lEPTB;Mz63PVg{PCEQvF2= MUDTRW5ITVJ?
HH MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwOEO4Olgh|ryP MoLoV2FPT0WU
769-P MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjQUY1KSzVyPUOuPFk2OSEQvF2= M2jRR3NCVkeHUh?=
CHP-212 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz4TWM2OD1|LkmyOVQ6KM7:TR?= M1\0NHNCVkeHUh?=
NCI-H82 NVK2NIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwOUW5N|Yh|ryP NID4OGNUSU6JRWK=
Mo-T NEjaWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33VWWlEPTB;ND6wOFMyOiEQvF2= NVTpfIU3W0GQR1XS
BB65-RCC NVrKc2xkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjUVlV{UUN3ME20MlA1Ozl7IN88US=> MXzTRW5ITVJ?
SW1990 M4OwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLGWVRKSzVyPUSuNFU6ODhizszN MYfTRW5ITVJ?
LK-2 M{PZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq4epVJUUN3ME20MlEyOjl|IN88US=> MU\TRW5ITVJ?
ES5 NY\TfHRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwMUO5PFUh|ryP MnzIV2FPT0WU
JVM-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTRwMUiyNlIh|ryP NEn4c4pUSU6JRWK=
RPMI-7951 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;3[pdiUUN3ME20MlIzPDF|IN88US=> NXPTZXFPW0GQR1XS
Calu-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\zZnhKSzVyPUSuNlc5QDFizszN MlPvV2FPT0WU
LC-2-ad MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjw[JlHUUN3ME20MlI6PTZ6IN88US=> NYrydJFSW0GQR1XS
SW954 M{e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TueWlEPTB;ND6yPVY3KM7:TR?= M1K5eXNCVkeHUh?=
H-EMC-SS MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwM{G4N|Eh|ryP Ml3WV2FPT0WU
ES3 M33XUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjzTWM2OD12LkO1OFQyKM7:TR?= MXnTRW5ITVJ?
no-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULDepVXUUN3ME20MlM2PTV2IN88US=> MlTjV2FPT0WU
LAN-6 NHLzOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLlOndKSzVyPUSuOFUyQDlizszN M{jnfXNCVkeHUh?=
FTC-133 NInXcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDxclZKSzVyPUSuOVM6PSEQvF2= NXK4W3c3W0GQR1XS
8505C MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m3d2lEPTB;ND61OFI{KM7:TR?= MWDTRW5ITVJ?
SW620 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwNUewOVch|ryP NGHNeWVUSU6JRWK=
BCPAP NGDiXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNe2lmUUN3ME20MlY{PDhzIN88US=> MVvTRW5ITVJ?
SK-LU-1 NV\CT|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n2UWlEPTB;ND62OlA5QSEQvF2= M1H1TnNCVkeHUh?=
NCI-H1623 M2rVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHFdFBKSzVyPUSuO|AzOjhizszN M1vhc3NCVkeHUh?=
C2BBe1 NE\EV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRwN{SwNFgh|ryP NWe5doU1W0GQR1XS
GP5d M4q2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHsTWM2OD12Lke4N|g5KM7:TR?= Ml3IV2FPT0WU
NB6 MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLvTWM2OD12Lki2NlA1KM7:TR?= NWS1Z3I4W0GQR1XS
MDA-MB-157 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrXTWM2OD12Lki4O|Yh|ryP M1;lW3NCVkeHUh?=
UMC-11 NFHJPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TzbGlEPTB;ND64PFk3PCEQvF2= MkPNV2FPT0WU
HCC1419 M1fvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[2cml7UUN3ME20MlkxODZ|IN88US=> NXrlXIpnW0GQR1XS
NCI-H2029 M2fYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzZ[pFKSzVyPUSuPVQyQDVizszN MVvTRW5ITVJ?
LXF-289 NYSzNlljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPGTWM2OD13LkCzO|E6KM7:TR?= NVHBbIpUW0GQR1XS
KINGS-1 M3m3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHHfFZKSzVyPUWuNFc4PDRizszN MXvTRW5ITVJ?
HD-MY-Z MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Le2lEPTB;NT6yN|k3QSEQvF2= MkTuV2FPT0WU
ESS-1 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHkTWM2OD13LkK1OVk4KM7:TR?= MmqzV2FPT0WU
GI-1 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTVwMke5NlYh|ryP NEPndnpUSU6JRWK=
RPMI-2650 NV6wU2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TWcGlEPTB;NT6zOlE3KM7:TR?= NEmxNYpUSU6JRWK=
IA-LM NWnVbW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj3TWM2OD13LkO5PFcyKM7:TR?= MojpV2FPT0WU
KP-4 NUL4fndZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjxSGlKSzVyPUWuOFY{OzRizszN NFvJ[JVUSU6JRWK=
G-402 M3\Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwNUG4OlUh|ryP MWXTRW5ITVJ?
OS-RC-2 NVnMN29lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PQbWlEPTB;NT61NlYxPCEQvF2= NH;3emtUSU6JRWK=
NCI-H1155 M4PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTVwNUS5OVUh|ryP M3r2[XNCVkeHUh?=
OE19 M3HKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzhTWM2OD13Lk[4OlI1KM7:TR?= NVOxSGQ1W0GQR1XS
U-2-OS NWn4[pA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrBdmhuUUN3ME21Mlg6ODF|IN88US=> MV3TRW5ITVJ?
SCC-15 M2fhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwZlVbUUN3ME21Mlk{PjZ{IN88US=> NX75XlZ[W0GQR1XS
NCI-H630 NH7T[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILmN4lKSzVyPUWuPVk1ODRizszN NGPN[pFUSU6JRWK=
PFSK-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;oNGlEPTB;Nj6wOVI2QSEQvF2= M1fmPXNCVkeHUh?=
NCI-H1770 NEnBWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPRc5dZUUN3ME22MlIxQDd2IN88US=> MkTwV2FPT0WU
SK-MEL-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HtOmlEPTB;Nj60NlkyPSEQvF2= M1zkbnNCVkeHUh?=
LB1047-RCC NGfvOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZwNEe2NlUh|ryP MULTRW5ITVJ?
NCI-H446 M13ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S1RmlEPTB;Nj62NlkzPSEQvF2= MWDTRW5ITVJ?
SW780 NWjSdYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfQOnpGUUN3ME22MlcxOTh3IN88US=> MlXkV2FPT0WU
NEC8 NYfvU3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDocItKSzVyPU[uO|Y3OyEQvF2= NHjxdJBUSU6JRWK=
NOMO-1 M{nhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHYOYdKSzVyPU[uO|gyOTFizszN MVrTRW5ITVJ?
COLO-668 NES5bGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnzVI9KSzVyPU[uPFQ{QDdizszN MXrTRW5ITVJ?
MC116 NX;aSYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rxc2lEPTB;Nj65N|g6PyEQvF2= NXr4TVJuW0GQR1XS
HCC1937 NYfrVopTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETn[VlKSzVyPU[uPVkzPTFizszN MmrsV2FPT0WU
NCI-N87 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq2bIlKSzVyPUeuNVkzQTNizszN Ml7ZV2FPT0WU
COLO-320-HSR M1TNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fwO2lEPTB;Nz6yNlc{QCEQvF2= MWrTRW5ITVJ?
HCC1806 M1fkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjKTWM2OD15LkK2NFQ1KM7:TR?= Mo\JV2FPT0WU
OVCAR-3 NVzFNZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvOSJhKSzVyPUeuN|MxOzhizszN NEDCdXNUSU6JRWK=
NUGC-3 NWTrVVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrQc2RmUUN3ME23MlM6Pjl2IN88US=> MlK5V2FPT0WU
SW1783 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\BSopKSzVyPUeuOFMyPzVizszN M1[2V3NCVkeHUh?=
GCT NIW2[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHhTWM2OD15LkW2PVA3KM7:TR?= NW\NXHJZW0GQR1XS
NCI-H2126 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\vTGpKSzVyPUeuO|M3OjVizszN NUSy[VFRW0GQR1XS
MEL-HO MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7MPHlKSzVyPUeuO|cxPTRizszN M3\JVnNCVkeHUh?=
CAPAN-1 NGO4VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfOeJhKSzVyPUeuO|c{PTdizszN M1HleHNCVkeHUh?=
SW756 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nrTmlEPTB;Nz63PFM{OyEQvF2= NXjKWWxxW0GQR1XS
SKG-IIIa M4DQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DB[mlEPTB;Nz64NVg6OiEQvF2= NXvaTFVGW0GQR1XS
HCE-T M3fpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LrbWlEPTB;Nz64O|c5OyEQvF2= NVXtZW9sW0GQR1XS
Ca-Ski NVLCO5hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;uSm9KSzVyPUeuPVk{QDNizszN MoLUV2FPT0WU
COLO-684 NHnIfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HQSmlEPTB;OD6wNVgyQCEQvF2= Ml3pV2FPT0WU
KYSE-70 NVrXW|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr5OVVKSzVyPUiuNFc4OjlizszN NGO0c2xUSU6JRWK=
TI-73 M4raOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThwMkW4OVEh|ryP NHS2SmhUSU6JRWK=
BT-20 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH0TWM2OD16LkK2NFUzKM7:TR?= MkHCV2FPT0WU
MHH-ES-1 NEfNUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRThwNUG4N|Qh|ryP NUTybpljW0GQR1XS
TE-12 M2XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj4U4ZKSzVyPUiuOVk6OzFizszN MYHTRW5ITVJ?
YH-13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vEOWlEPTB;OD62NVAxQCEQvF2= NFjRe5NUSU6JRWK=
SF126 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\UR2lEPTB;OD64N|g3PSEQvF2= M1f2eXNCVkeHUh?=
J82 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[1dmlEPTB;OD65NFA{QCEQvF2= MmKyV2FPT0WU
RCC10RGB NUjlVXdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnyW4h1UUN3ME24Mlk6PTZzIN88US=> NWrTS2p1W0GQR1XS
SK-UT-1 NEDZbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rWS2lEPTB;OT6wOFk1PSEQvF2= MnzGV2FPT0WU
LB2241-RCC NILHcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXyTWM2OD17LkG5NVM4KM7:TR?= NFPrOHdUSU6JRWK=
LB996-RCC M3zBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTlwMUm4PUDPxE1? NFLzRYFUSU6JRWK=
EPLC-272H M1nKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;nOXNIUUN3ME25MlM4PjV5IN88US=> M1HacHNCVkeHUh?=
CTV-1 MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf4TWM2OD17LkW2OVMzKM7:TR?= MkWzV2FPT0WU
HSC-2 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\TVHdKSzVyPUmuOVc2PSEQvF2= MUXTRW5ITVJ?
SK-MEL-28 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXJWWNrUUN3ME25MlYyQDl|IN88US=> M1qw[nNCVkeHUh?=
MMAC-SF M{G4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTlwNki3OUDPxE1? M2m2SXNCVkeHUh?=
CP50-MEL-B MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXMUm1KSzVyPUmuO|U4QDJizszN MVnTRW5ITVJ?
HT-1080 NUTFOVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfGRopKSzVyPUmuO|c4OzlizszN MlPDV2FPT0WU
HEC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXftU3lrUUN3ME2xNE4{OzV{IN88US=> M1rD[3NCVkeHUh?=
AGS NHzkemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjtWmRKSzVyPUGwMlM4PCEQvF2= M33abHNCVkeHUh?=
GAMG NH;QTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofyTWM2OD1zMD61NVYzKM7:TR?= MUXTRW5ITVJ?
SW48 M2q0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HGPWlEPTB;MUCuOVE5QSEQvF2= Mm\yV2FPT0WU
U031 NULSWndyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPCT|FKSzVyPUGwMlU6ODhizszN NEjXeYVUSU6JRWK=
OVCAR-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXMWXFIUUN3ME2xNE43PDJ7IN88US=> M4HNb3NCVkeHUh?=
SF295 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvrV5hEUUN3ME2xNE43PzB2IN88US=> NVTjeYtlW0GQR1XS
BHT-101 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\HTWM2OD1zMD63NVc4KM7:TR?= M3HySXNCVkeHUh?=
VMRC-RCZ MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfDcoJKSzVyPUGxMlMzODFizszN M17lbHNCVkeHUh?=
ACHN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFzLkSyNVEh|ryP NFnudZhUSU6JRWK=
NCI-H526 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT3WmUzUUN3ME2xNU42ODR|IN88US=> NVu4WFM6W0GQR1XS
MN-60 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK5SnpKSzVyPUGxMlU{QSEQvF2= M161[nNCVkeHUh?=
NCI-H2291 M1XNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnlSllKSzVyPUGxMlU1PjZizszN MmriV2FPT0WU
SCC-25 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTI[WJKSzVyPUGxMlc2PTZizszN M2[4OXNCVkeHUh?=
SK-MEL-2 M2LJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX1R|JrUUN3ME2xNU44PjN5IN88US=> MU\TRW5ITVJ?
SN12C M2K3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFzLkmzOVUh|ryP MVzTRW5ITVJ?
NCI-H69 M{Pwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnHTWhYUUN3ME2xNk41OjN2IN88US=> NW[5PWFVW0GQR1XS
ME-180 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\TTWM2OD1zMj63NFU1KM7:TR?= M3SxdHNCVkeHUh?=
MC-IXC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF{Lke1NVgh|ryP MlvkV2FPT0WU
NCI-H2347 NHzT[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF{Lke2NVQh|ryP MVTTRW5ITVJ?
M059J M3XDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe0TWM2OD1zMj63O|I4KM7:TR?= MVnTRW5ITVJ?
A2058 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi2VZNKSzVyPUGyMlg3QDFizszN M{PaWHNCVkeHUh?=
VA-ES-BJ MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDGTmhKSzVyPUGyMlg4QDVizszN NW\n[FduW0GQR1XS
Ca9-22 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zzfWlEPTB;MUKuPVQ2OSEQvF2= MYXTRW5ITVJ?
KNS-42 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCwTWM2OD1zMj65PVg1KM7:TR?= NGfvRmZUSU6JRWK=
LoVo NXLRVXZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e3SmlEPTB;MUOuNlMyOyEQvF2= M1jsNnNCVkeHUh?=
AM-38 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fl[GlEPTB;MUOuNlU3PiEQvF2= MX7TRW5ITVJ?
NB5 NI[0d3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjnOWg3UUN3ME2xN{4{PzV{IN88US=> MV7TRW5ITVJ?
L-363 NVOxcHk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnVV2hHUUN3ME2xN{41ODN|IN88US=> MXfTRW5ITVJ?
SK-MEL-30 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF2LkC2OFUh|ryP MoTYV2FPT0WU
NCI-H1563 NWTKUVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETrbGZKSzVyPUG0MlYxOzlizszN MnvNV2FPT0WU
NCI-H2228 M4r6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\JeoN6UUN3ME2xOE43ODd5IN88US=> M2nDfHNCVkeHUh?=
MFM-223 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HHeWlEPTB;MUWuNVgyOyEQvF2= M2XQVHNCVkeHUh?=
LB831-BLC M4LTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzNVFltUUN3ME2xOU4zPzZ5IN88US=> M{TKZXNCVkeHUh?=
SW872 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvHTWM2OD1zNT6zNFg3KM7:TR?= Mk\vV2FPT0WU
NCI-H522 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DxNGlEPTB;MUWuN|MxPiEQvF2= NVPo[WdTW0GQR1XS
EW-1 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDoTWM2OD1zNT61OFYzKM7:TR?= M4P5cXNCVkeHUh?=
HN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TVdWlEPTB;MUWuOVk1OiEQvF2= NIrIZ2hUSU6JRWK=
SW837 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF3Lke4OFch|ryP MYHTRW5ITVJ?
SCC-9 NIraT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF3LkixNVQh|ryP M1\FUHNCVkeHUh?=
MKN7 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TxfGlEPTB;MUWuPVc{OiEQvF2= NXHudJVpW0GQR1XS
KYSE-410 NHLiXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF4LkW5NUDPxE1? NGXSTIRUSU6JRWK=
SK-N-DZ NEHj[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF4Lk[xNVYh|ryP NILtfItUSU6JRWK=
COR-L105 NHLXTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lhe2lEPTB;MU[uOlUzQCEQvF2= MmjCV2FPT0WU
LB2518-MEL NVLFWldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF4LkizPFkh|ryP MnjwV2FPT0WU
OVCAR-4 NWiwWZZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\NTmlEPTB;MU[uPFg3OiEQvF2= MnnPV2FPT0WU
TK10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXETopPUUN3ME2xOk46PDd|IN88US=> NWP1eYd5W0GQR1XS
KNS-62 NFrKToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPqSYFKSzVyPUG2Mlk4PzdizszN NFzBZ4lUSU6JRWK=
RPMI-8866 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF5LkG3N|Ih|ryP MUXTRW5ITVJ?
HuP-T4 MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF5LkK0PVUh|ryP NY\2TIdIW0GQR1XS
CGTH-W-1 NEfkW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC0TWM2OD1zNz61NlE6KM7:TR?= MmrQV2FPT0WU
T-24 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnzfodiUUN3ME2xO{42OzR5IN88US=> NVezS4t1W0GQR1XS
HT-3 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvzZmxKSzVyPUG3MlU6OTRizszN NXuyTZdqW0GQR1XS
KS-1 NVL4cpY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jMeWlEPTB;MUeuOlc{KM7:TR?= M1nFeXNCVkeHUh?=
NCI-H1792 NHfKSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XTXmlEPTB;MUeuO|k5KM7:TR?= NYL4fJBWW0GQR1XS
ABC-1 NWnDSWh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrGS5NvUUN3ME2xO{45OTRzIN88US=> Mn75V2FPT0WU
BPH-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGftSpFKSzVyPUG4MlE3QDVizszN MlTlV2FPT0WU
A431 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnETWM2OD1zOD60NVI4KM7:TR?= NYfSW4pIW0GQR1XS
T98G MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT2TWM2OD1zOD61NVU4KM7:TR?= NYnRZ|RoW0GQR1XS
BHY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPGTWM2OD1zOD64Olkh|ryP NXHMRWJiW0GQR1XS
Capan-2 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16zVGlEPTB;MUiuPVA4QCEQvF2= M{HEZnNCVkeHUh?=
MDA-MB-175-VII NYDTfmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HQ[mlEPTB;MUiuPVIxQSEQvF2= M37KSnNCVkeHUh?=
CAL-27 M1PsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\zOphtUUN3ME2xPU4xPDh5IN88US=> M4LjNnNCVkeHUh?=
AsPC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LNRWlEPTB;MUmuPFY2PyEQvF2= MUjTRW5ITVJ?
KU812 M4D4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPYTWM2OD1zOT65OVc{KM7:TR?= MY\TRW5ITVJ?
NCI-H441 NUewWpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXJRlNKSzVyPUKwMlAxOSEQvF2= MVfTRW5ITVJ?
Mewo M1fXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJyLkGyPFgh|ryP NVS4TIZyW0GQR1XS
SK-MEL-24 NXL5OIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLJPHd4UUN3ME2yNE4yPDd5IN88US=> M2XndXNCVkeHUh?=
NCI-H727 NU\GSIw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJyLkK3NFQh|ryP NEmyOpBUSU6JRWK=
EKVX Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHXd4pKSzVyPUKwMlYxPiEQvF2= NXL1TVVwW0GQR1XS
RT-112 Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknMTWM2OD1{MD62NVIzKM7:TR?= NF;Ce4JUSU6JRWK=
CAMA-1 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\zWJpKSzVyPUKwMlk5ODNizszN MUPTRW5ITVJ?
SW900 M1\zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvxTWM2OD1{MT6wNVQ6KM7:TR?= M4LscHNCVkeHUh?=
NCI-H23 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HXOWlEPTB;MkGuNVI4PyEQvF2= MlO4V2FPT0WU
SK-PN-DW NVrLdHhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJzLkG2OFkh|ryP M{DrOnNCVkeHUh?=
BB30-HNC Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH4cVNrUUN3ME2yNU4zPzR3IN88US=> M4DBWHNCVkeHUh?=
VM-CUB-1 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfaWphPUUN3ME2yNU4{PTN4IN88US=> M3vwR3NCVkeHUh?=
IST-MEL1 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7o[mtKSzVyPUKxMlM3QTJizszN NVzuc|NUW0GQR1XS
CTB-1 NI\4dFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWwTlBuUUN3ME2yNU41PzV3IN88US=> NWXGcXdFW0GQR1XS
LCLC-103H NHjCfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ{LkG1PFIh|ryP M3TnOXNCVkeHUh?=
PANC-03-27 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHJPYpKSzVyPUKyMlUyPjlizszN NWfrUG0yW0GQR1XS
HTC-C3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ{LkW1OVUh|ryP MYfTRW5ITVJ?
TE-8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWni[lRUUUN3ME2yN{4zPTZ3IN88US=> NUewT|lzW0GQR1XS
NCI-H292 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ3LkO1N|Yh|ryP M33wNnNCVkeHUh?=
COLO-680N M33rW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\1dJVFUUN3ME2yOU43OzJ7IN88US=> Ml7JV2FPT0WU
KYSE-520 M3izXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjmV|NKSzVyPUK1MlY1PCEQvF2= MWXTRW5ITVJ?
NB10 NFPzN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHkTWM2OD1{Nj6zNVE4KM7:TR?= M1nUb3NCVkeHUh?=
NCI-H661 NUSwPJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLQOpRiUUN3ME2yOk41PzF|IN88US=> NI\GZYRUSU6JRWK=
GMS-10 NWrke2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPY[XBKSzVyPUK2Mlg3OzhizszN NWXBS|g{W0GQR1XS
NCI-H2122 NHLhdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ4Lkm5PVgh|ryP MWrTRW5ITVJ?
OVCAR-8 M13CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXxTWM2OD1{Nz6wOlM5KM7:TR?= NHHm[npUSU6JRWK=
DJM-1 NYOySlhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ5LkG0OVQh|ryP NV35Z|dMW0GQR1XS
UACC-893 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDVbJdKSzVyPUK3Mlk5PzhizszN NHezc5VUSU6JRWK=
C8166 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LhbGlEPTB;MkiuOlk{QCEQvF2= NVrmRWJPW0GQR1XS
NCI-H1693 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnsOI1lUUN3ME2yPE43QTd3IN88US=> MkL4V2FPT0WU
TYK-nu NXnpbY9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjGSmdKSzVyPUOwMlA{PDVizszN MljmV2FPT0WU
SW1710 NUjuPWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNyLkGyOkDPxE1? NWfqOIRLW0GQR1XS
A375 NXmwcZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNyLkOyOFMh|ryP MXvTRW5ITVJ?
HMV-II NH;UdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWxTWM2OD1|MT6zOVkzKM7:TR?= MmnsV2FPT0WU
NCI-H2087 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfPTWM2OD1|MT62N|UzKM7:TR?= MlK3V2FPT0WU
CAL-54 M1jHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn4TWM2OD1|MT63NlQyKM7:TR?= M2rSe3NCVkeHUh?=
HCC70 M1;Sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN{LkGzPFch|ryP MoXEV2FPT0WU
ES1 NXnWRYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GybWlEPTB;M{KuN|A3OiEQvF2= MojwV2FPT0WU
NCI-H1355 NGXKdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH3clhKSzVyPUOzMlIxPCEQvF2= MXHTRW5ITVJ?
CFPAC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\JbpRCUUN3ME2zN{4zOzN{IN88US=> MnvJV2FPT0WU
MKN28 NVztTGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN|LkO4NFkh|ryP NVnncGVEW0GQR1XS
HDLM-2 NEjMOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XmbWlEPTB;M{OuOlk{OSEQvF2= NV34cGVGW0GQR1XS
PANC-10-05 NGHVdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe3WZJHUUN3ME2zOE4yODF2IN88US=> NFTmU49USU6JRWK=
SAS MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr3W29KSzVyPUO0MlQ2PjVizszN M2LzWHNCVkeHUh?=
HCC1395 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrIUmlXUUN3ME2zOE44OTh4IN88US=> M4\1ZXNCVkeHUh?=
8305C NHSwO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN3Lki0NVUh|ryP M2XKTHNCVkeHUh?=
KM12 NW\iTlN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\kZ4RKSzVyPUO2Mlc2PDdizszN M32zN3NCVkeHUh?=
SW1116 M3L0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[3[WlEPTB;M{euOVk6OiEQvF2= NXHz[5k4W0GQR1XS
SK-MEL-1 NFSyO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN6LkOzPFkh|ryP M3fqSXNCVkeHUh?=
HCC2218 NXTCXmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN6Lk[1NVkh|ryP MWTTRW5ITVJ?
T84 NWD0RVh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN6Lke0NFkh|ryP M3rseHNCVkeHUh?=
ETK-1 NYTTS255T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX4TWM2OD1|OT6wNlIh|ryP NGTuSXdUSU6JRWK=
COLO-800 NIrmT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HB[2lEPTB;M{muN|g3QCEQvF2= NX7tSFdYW0GQR1XS
CAL-12T M1T6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfTTWM2OD1|OT61NlgyKM7:TR?= MYrTRW5ITVJ?
ACN Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nwXmlEPTB;NECuOFkyOSEQvF2= NGjSNIpUSU6JRWK=
SJSA-1 NVfzfXlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXoTWM2OD12MT6xOVk3KM7:TR?= M2DRZnNCVkeHUh?=
PSN1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTRzLkG3OFkh|ryP MV3TRW5ITVJ?
D-566MG NGD0TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHqT2lKSzVyPUSxMlIxQDZizszN MWnTRW5ITVJ?
EGI-1 NF7EUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTR{LkSyPEDPxE1? M{e4WXNCVkeHUh?=
A204 NIjqVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR{Lk[zPFgh|ryP MnLIV2FPT0WU
Saos-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfDcZBKSzVyPUSyMlg{PjlizszN NUHtPGpDW0GQR1XS
SNU-C2B M2LWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;4Xo1EUUN3ME20N{43QDd6IN88US=> Mn7KV2FPT0WU
HLE NXnwVXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPrTWM2OD12ND6wPFU3KM7:TR?= NXWzTIVXW0GQR1XS
SW1463 NF\udXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:xXod3UUN3ME20OE46QTdzIN88US=> Mn\RV2FPT0WU
DSH1 NGLUV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTR3LkCwN|Mh|ryP MoHXV2FPT0WU
MCF7 NUDsfGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHqTWM2OD12NT61NFUyKM7:TR?= NIO0VIxUSU6JRWK=
K5 NH3iSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvIVYtDUUN3ME20OU46PDB3IN88US=> MojVV2FPT0WU
NCI-H358 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnmUYNKSzVyPUS3MlIyPSEQvF2= MXjTRW5ITVJ?
NCI-H2030 NXvkUmFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR5LkKzO|Qh|ryP NFHQSFZUSU6JRWK=
SW948 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTR5LkS2OEDPxE1? NX3kU2tFW0GQR1XS
BALL-1 M1XjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfzN2h4UUN3ME20O{43OTZ6IN88US=> MlLPV2FPT0WU
TE-9 M3T4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR5Lkm1PFEh|ryP M{\MfXNCVkeHUh?=
SK-N-FI M4XDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK5NZFRUUN3ME20PE4xOzV6IN88US=> NGHyR|BUSU6JRWK=
KALS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR6LkGyPFkh|ryP M3rHZXNCVkeHUh?=
HO-1-N-1 NYfDR|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzFOVFKSzVyPUS4Mlc1PDVizszN MkmwV2FPT0WU
NCI-H2452 M3Syfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\Ke2lEPTB;NEmuNVE2OiEQvF2= NIj2b2tUSU6JRWK=
OC-314 NGnrTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12zdmlEPTB;NEmuOlg{PCEQvF2= MWHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID